Ecuador Research Use Only (RUO) Products: Exemption Rules and Compliance Boundaries

1. Key takeaways

Article 3 of the new regulation brings RUO (Research Use Only) products into the regulatory definition system for the first time, and Article 29(b) provides that devices used for research in a scientific setting and not intended for commercialization are exempt from registration. The sole substantive criterion for the RUO channel is whether commercialization is intended, not whether the product label carries the letters RUO. The exemption therefore turns on purpose and conduct, and both the importer and the end user must be able to evidence the research use if challenged.

2. Legal basis

Substance of the official text of Article 29(b): devices for research use conducted in a scientific environment, and whose purpose is not commercialization, do not require sanitary registration. The exemption operates alongside, and must be read together with, the mandatory registration rule of Article 5, which covers everything marketed within the scope of the regulation.

3. Expert insights

Insight 1: RUO has moved from a labeling practice to a statutory definition. Until now, exporting under the label of research use was an industry convention; with the new regulation writing it into the Article 3 definitions, RUO becomes a state with legal meaning, whose boundaries are delineated by Article 29(b). This elevation from custom to statute changes both the risk profile and the evidentiary expectations attached to research shipments.

Insight 2: the test is purpose, not labeling, and this determines the direction of proof. The wording of Article 29(b) is not intended for its commercialization. This means:

• Products bearing an RUO label but actually entering commercial sales channels do not meet the exemption conditions;
• Products without an RUO label but genuinely used in-house by a research institution with no sales activity may meet the exemption conditions.

Insight 3: the burden of proof lies with the user and the importer. Because the test is purpose, the importer and the end user must be able to demonstrate the research use of the product, for example through procurement documents of the research institution, ethics review materials, or evidence that no sales took place. Chinese exporters should state the use restriction expressly in contracts and retain supporting files. A clean paper trail at shipment time is far cheaper than reconstructing evidence after an inspection.

Insight 4: the RUO exemption and the free commercialization of low-risk devices are two different channels and must not be mixed. General provision 5 provides that low-risk devices and condoms may be freely commercialized (while still complying with the regulation and the Health Organizations Law); Article 29(b) is an exemption for research use (with no commercialization). The former can be sold but carries obligations; the latter avoids registration but permits no sales. Confusing the two leads either to unregistered commercial sales or to unnecessary registration spending.

Insight 5: the RUO risk is highest in the IVD field. In vitro diagnostic reagents exported as RUO and later diverted to clinical use are a priority concern for regulators everywhere. The two red lines of Article 30 (prohibited ingredients and sanitary alerts) apply equally to RUO products; what is exempted is the registration obligation, not the product safety floor. A diverted RUO reagent used for clinical decisions can trigger enforcement even though the original shipment was lawful.

Insight 6: Article 29(b) and Article 29(d) together form the two non-commercialization exemptions. Item (b) covers research-use devices and item (d) covers control software without an independent medical purpose. Their common feature is the absence of an independent commercialized medical purpose. Reading them together clarifies that the regulation exempts only products outside the commercial medical sphere, and that any step toward the market removes the exemption.

4. Practical recommendations

1. Do not use RUO to circumvent registration: wherever sales occur, register through the normal pathway.
2. Write express research-use restriction clauses into export contracts and require the importer to issue a use declaration.
3. Maintain an RUO shipment register recording the receiving institution, the use and the quantities, ready for inspection.
4. Keep the RUO channel separate from the low-risk free commercialization channel; do not confuse the boundaries of the two obligation sets.
5. Apply strict standards to IVDs: where clinical use is possible, register as DMDIV without exception.

5. Verification checklist

• □ Confirmed absence of commercial sales activity (where the RUO exemption applies)
• □ Research-use restriction clause written into the export contract
• □ Use declaration obtained from the importer or end user
• □ RUO shipment register established (institution, use, quantity)
• □ Confirmed that the product contains no prohibited ingredients and is not subject to a sanitary alert
• □ IVD products either excluded from possible clinical use or registered as DMDIV

Regulatory information verified as of October 29, 2026

Core service areas

1. Global market access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, plus premarket registration pathway planning and filing execution across Latin America, Southeast Asia, the Middle East and other markets.
2. Authorized representative services: EU authorized representative (EC REP), UK responsible person (UK RP), Swiss authorized representative (CH REP), Australia sponsor and US Agent, together with neutral certificate-holder structure design.
3. Quality system compliance: ISO 13485 implementation and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) authoring and remediation.
4. Clinical and evaluation: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why GRZAN

• Local regulatory teams: filings in each target market are executed by locally licensed regulatory professionals and prepared directly in the official language of the market, without secondary translation.
• Neutral holding structure: certificate-holding arrangements that are not tied to any distribution channel, keeping registrations independent of channel partners.
• Regional leverage: a single technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance cost.
• Full lifecycle support: end-to-end service from classification, pathway design and dossier preparation through certificate holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides medical device registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, certificate-holding structure design, official fee and timeline estimation

*This volume was prepared by the GRZAN regulatory team; regulatory information verified as of October 29, 2026.*